I

Innate Pharma SA
D

IPHA

2.14000
USD
-0.06
(-2.73%)
مغلق
حجم التداول
331
الربح لكل سهم
-1
العائد الربحي
-
P/E
-3
حجم السوق
197,232,989
أصول ذات صلة
A
ADMA
0.245
(1.36%)
18.270 USD
A
AKBA
-0.09500
(-2.64%)
3.50500 USD
A
ARDX
-0.06000
(-1.40%)
4.21500 USD
B
BCRX
-0.17500
(-2.12%)
8.09000 USD
F
FGEN
-0.19000
(-2.63%)
7.04000 USD
INSM
INSM
3.230
(3.17%)
104.980 USD
K
KPTI
-0.37000
(-8.31%)
4.08000 USD
M
MDGL
0.71
(0.24%)
294.56 USD
X
XNCR
-0.22000
(-2.44%)
8.81000 USD
المزيد
الأخبار المقالات

العنوان: Innate Pharma SA

القطاع: Healthcare
الصناعة: Biotechnology
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.